Improving oral absorption to rapidly advance early phase compounds

Tuesday, October 18, 2022

11:15 AM – 12:00 PM ET

Location:Spotlight Stage 2, Exhibit Hall A&B

Presented By Lonza

Chalk Talk Presenter(s)

Deanna Mudie, PhD

Sr. Principal Engineer R&D
Lonza Small Molecules
Bend, Oregon

Handouts

Description: Amorphous solid dispersions (ASDs) are an important formulation strategy for improving oral absorption of poorly water-soluble drugs. To achieve robust ASD drug products, pharmaceutical scientists must design ASD formulations to attain several key attributes including in vivo performance, stability, and manufacturability while minimizing dosage form size. Combining knowledge of key drug, polymer and gastrointestinal properties together with an in vitro and in silico toolkit is critical for achieving key ASD attributes while reducing development timelines and drug substance requirements.

Learning Objectives:

Learn how Lonza’s custom and off-the-shelf in vitro and in silico tools can be combined to streamline ASD formulation development
Gain knowledge about how drug and polymer properties, drug loading and dosage form architecture can influence ASD in vitro and in vivo performance
Learn how to maximize drug loading in ASD dosage forms while still achieving good performance, stability and manufacturability